Due in large part to the mainstream media, most of the US population has targeted MDMA as a dangerous drug that only leads to the loss of young lives at electronic music events. But what the media fails to mention is that since the drug was first synthesized in 1912, MDMA has been a highly discussed topic among psychologists as a possible means of therapy. Following successful trials in Switzerland with the drug to help treat PTSD, anxiety, and other disorders, the FDA is now considering giving the green light for trials in the US to commence in 2021.
Some progress has already been made in this respect; in May, the FDA granted Dr. Phillip Wolfson in San Francisco permission to carry out a study with 18 patients. In 2017, agreements for a third phase of trials – which will treat an even larger group – are expected to be solidified between the FDA and the Multidisciplinary Association for Psychedelic Studies. A spokesperson from the Multidisciplinary Association for Psychedelic Studies recently confirmed at the Horizons: Perspectives on Psychedelics conference that they are on the right path to getting full approval by 2021.